Skip to main content

Advertisement

SpringerLink
Log in

Hepatologie

Leberfibrose - Diagnostik und innovative Therapieansätze

  • Zertifizierte Fortbildung
  • Published:
Gastro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© N. Röhlen et al.

2

© N. Röhlen et al.

Literatur

  1. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38:Suppl 1:2-6.

  2. Kim D et al. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018;155(4):1154-63.e3.

  3. Urban S et al. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70(9):1782-94.

  4. Bataller R et al. Liver fibrosis. J Clin Invest. 2005;115(2):209-18.

  5. Rockey DCet al. Fibrosis--a common pathway to organ injury and failure. N Engl J Med. 2015;372(12):1138-49.

  6. Roehlen N et al. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020;9(4):875.

  7. Bataller R et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004;126(2):529-40.

  8. Saile Bet al. Fibrogenese-Zirrhose. Gastroenterologe.2007;4:228-37.

  9. EASL Clinical Practice Guideline Panel. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-89.

  10. Boyum JH et al. Incidence and Risk Factors for Adverse Events Related to Image-Guided Liver Biopsy. Mayo Clin Proc. 2016;91(3):329-35.

  11. Schwarzer R, Ferlitsch A. Liver Biopsy-Transjugular. Clin Liver Dis (Hoboken). 2014;4(5):113-5.

  12. Roeb AE et al. Leitlinie der aktualisierten S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (DGVS). April 2022 - AWMF-Registernummer: 021-025

  13. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598-607.

  14. Shah AG et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-12.

  15. Peleg N et al. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. Dig Liver Dis. 2017;49(10):1133-8.

  16. Boursier J et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65(3):570-8.

  17. Catanzaro R et al. FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study. Clin Exp Hepatol. 2021;7(1):111-6.

  18. Leroy V et al. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61(1):28-34.

  19. Angulo P et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.

  20. Ruffillo G et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011 Jan;54(1):160-3.

  21. Shaheen AAM et al. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102(11):2589-600.

  22. Chen J, Liu C, Chen H, Liu Q, Yang B, Ou Q. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation. J Clin Lab Anal. 2013 Jan;27(1):5-11.

  23. Moreno C et al. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019;70(2):273-83.

  24. Calès P et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42(6):1373-81.

  25. Halfon P et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46(3):395-402.

  26. Calès P et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50(1):165-73.

  27. Guha IN et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47(2):455-60

  28. Rosenberg WMC et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127(6):1704-13.

  29. Zhang YNet al. Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. J Magn Reson Imaging. 2020;51(1):25-42.

  30. Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology. 2014 Apr 15;2014:1-15.

  31. Castéra L et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-50.

  32. Vergara S et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2007 Oct 15;45(8):969-74.

  33. Marcellin P et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009 Feb;29(2):242-7.

  34. Corpechot C et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology. 2006;43(5):1118-24.

  35. Yoneda M et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56(9):1330-1.

  36. Nahon P et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol. 2008;49(6):1062-8.

  37. Herrmann E et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. Hepatology. 2018;67(1):260-72.

  38. Lassailly G et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290-1301.e5.

  39. Marcellin P et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-75.

  40. D'Ambrosio R et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532-43.

  41. Younossi ZM et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-96.

  42. Manatsathit W et al. Accuracy of liver stiffness, spleen stiffness, and LS-spleen diameter to platelet ratio score in detection of esophageal varices: Systemic review and meta-analysis. J Gastroenterol Hepatol. 2018;33(10):1696-706.

  43. de Franchis R et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959-74.

  44. Marasco G et al. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients. Hepatol Int. 2020 Sep;14(5):850-7.

  45. Wang J et al. Liver stiffness measurement predicted liver-related events and all-cause mortality: A systematic review and nonlinear dose-response meta-analysis. Hepatol Commun. 2018;2(4):467-76.

  46. Singh S et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(12):1573-84.e1-2; quiz e88-9.

  47. Bitzer M et al. S3-Leitlinie - Diagnostik und Therapie des Hepatozellulären Karzinoms.Langversion 2.0 - Juni 2021 AWMF-Registernummer: 032 - 053OL

  48. Harrison SA et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26-39.

  49. Guirguis E et al. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. Pharmacotherapy. 2021;41(3):315-28.

  50. Harrison SA et al. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatol Commun. 2021;5(4):573-88.

  51. Ratziu V et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021;27(10):1825-35.

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany

    Natascha Röhlen &  Robert Thimme

  2. - Universitätsklinikum Freiburg -, Klinik f. Innere Medizin II/Gastroenterologie, Hugstetter Str. 55, 79106, Freiburg/Brsg., Germany

    Tobias Böttler

Authors
  1. Natascha Röhlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Thimme
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias Böttler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natascha Röhlen.

Ethics declarations

Die Autorin und die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: keine. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Röhlen, N., Thimme, R. & Böttler, T. Leberfibrose - Diagnostik und innovative Therapieansätze. Gastro-News 9, 40–50 (2022). https://doi.org/10.1007/s15036-022-3108-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-022-3108-8

Search

Navigation